FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB 3235Number: 0104
Expires: 2011
Estimated average
burden hours per
response... 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)										
1. Name and Address of Reporting	;	2. Date of Eve	ent Requiring	3. Issuer Nan	3. Issuer Name and Ticker or Trading Symbol					
Person *		Statement		Tonix Pharmaceuticals Holding Corp. [TNXP]						
DAVIDSON STUART		(Month/Day/\) 01/14/2013	Year)							
(Last) (First) (Midd	dle)	-01/14/2013		4. Relationship of Reporting			5. If Amendment, Date Original Filed(Month/Day/Year)			
C/O TONIX				Person(s) to Issuer						
PHARMACEUTICALS				(Check all applicable) X Director 10% Owner						
	HOLDING CORP, 509				Officer (give Other (specify			7		
MADISON AVENUE, STE	306			title below)	title below) below)					
(Street)								al or Joint/Group		
NEW YORK, NY 10022								k Applicable Line) ed by One Reporting Person		
NEW TORK, NT 10022							Form file	ed by More than One		
(0)							Reporting Pe			
(City) (State) (Zi	.p)	Table I - Non-Derivative Securities Beneficially Owned								
			2. Amount of Securities		3.			ure of Indirect Beneficial		
(Instr. 4)			Beneficially Owned		Ownership Owner		•			
			(Instr. 4)		Form: Direct (Instr. 5) (D) or					
					Indirect (I)					
					(Instr. 5)					
Common Stock, Par Value \$0.001			1,324,049		I	Lysa	Lysander, LLC (1)			
Common Stock, Par Value \$0.001			130,906	I Oyst		stercatcher Trust (1)				
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)										
Persons who respond to the collection of information contained in this form are not										
required to respond unless the form displays a currently valid OMB control number.										
number.										
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										
1. Title of Derivative Security 2. Date Exercisable a		Exercisable and	d 3. Title and Amount of		of 4. 5.		5.	6. Nature of Indirect		
(Instr. 4) Expiration Date		Securi	Securities Underlying		Conversion O		Beneficial Ownership			

1. Title of Derivative Security (Instr. 4)	2. Date Exerci Expiration Da (Month/Day/Yea	te	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of	Ownership	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
	Date Exercisable	Expiration Date		Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)		
Warrants	01/20/2012	01/20/2017	Common Stock	50,000	\$ 1.25	I	Lysander, LLC (1)	
Warrants	12/04/2012	12/04/2017	Common Stock	166,667	\$ 0.6	I	Lysander, LLC (1)	
Warrants	12/04/2012	12/04/2013	Common Stock	166,667	\$ 0.4	I	Lysander, LLC (1)	

Reporting Owners

Reporting Owner Name / Address	Relationships
Keborung Owner Name / Address	

		Director	10% Owner	Officer	Other	
DAVIDSON STUART						l
C/O TONIX PHARMACEUTICA	LS HOLDING CORP	v				ı
509 MADISON AVENUE, STE	306	Λ				ı
NEW YORK, NY 10022						ı

Signatures

/s/ Stuart Davidson	01/14/2013
***Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Reporting person may be deemed to be a control person of this entity.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.